FormalPara Key Summary Points
Why carry out this study?
Migraines associated with menstruation are typically more debilitating than non-menstrual migraines, of longer duration, and less responsive to pharmacological treatments.
Remote electrical neuromodulation (REN) is a non-pharmacological abortive treatment for migraine headache.
The current study evaluated the self-reported effectiveness and tolerability of REN for the abortive treatment of menstrual migraine.
What was learned from the study?
REN was reported effective for menstrual migraine by most participants, and was very well tolerated.
The study suggests that REN may provide a safe, non-pharmacological alternative for the acute treatment of menstrual migraine.

Digital Features

This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to


Migraine is the world’s second cause of years lived with disability, and the first cause among young women [1]. It is characterized by recurrent headache attacks that are often accompanied by nausea, vomiting, photophobia, and phonophobia [2]. About 60% of women who suffer from migraines experience attacks that are associated with menstruation [3]. Menstrual migraine is often more painful, more disabling, of longer duration, and less responsive to treatment [4].

Menstrual migraine is mainly managed by the same acute treatments as those used for non-menstrual migraine, including triptans and non-steroidal anti-inflammatory drugs (NSAIDs) [5]. However, these treatments have been shown to be less effective for menstrual migraines [6], thus possibly resulting in more frequent use and higher doses, which in turn are associated with medication overuse headache and migraine chronification [7, 8]. Pharmacotherapy in menstrual migraine is further complicated by the lack of strong evidence-based recommendation, the involvement of hormones, and in some cases the use of contraceptives [9].

Recent developments introduced several non-pharmacological neuromodulation approaches for the treatment of migraine [10]. The integration of neuromodulation into migraine care is recommended for suitable patients by both European and American Headache associations [11, 12]. One of these is remote electrical neuromodulation (REN). REN stimulates mainly C and Aδ fibers in the upper arm to activate an endogenous analgesic mechanism termed conditioned pain modulation (CPM) [13,14,15] (see Fig. 1). Efficacy studies have demonstrated that REN is safe and clinically beneficial for the acute treatment of migraine in adults with episodic migraine [16,17,18,19,20,21,22], adults with chronic migraine [23], and adolescents with migraine [24]. A comparison of the efficacy of REN to that of acute migraine medications indicated that REN has non-inferior efficacy compared to the tested acute migraine therapies [20]. A recent meta-analysis further found that REN was the only migraine neuromodulation intervention for which there is sufficient high-quality research, and thus the only one for which efficacy was well established [25].

Fig. 1
figure 1

REN’s principle of operation. a Schematic illustration of the principle of operation of REN (modified with permission from Yarnitsky et al. [17]; Headache). The device stimulates C and Aδ noxious sensory fibers of the upper arm above their depolarization threshold yet below the perceived pain threshold. The noxious information reaches the brainstem through the ascending pain pathway (black). This information activates the descending pain inhibitory pathway (green), involving the brainstem pain regulation center (which includes the PAG, RVM, and SRD), which inhibit incoming messages of pain in the trigeminal cervical complex (TCC) that occur during a headache of a migraine attack (red). PAG periaqueductal gray, RVM rostral ventromedial medulla, SRD subnucleus reticularis dorsalis, TCC trigeminal cervical complex. b An image of the device as it is worn on the arm during treatment

The aim of this survey study was to evaluate the reported effectiveness, satisfaction, and safety of REN for the treatment of menstrual migraine in women who use REN as part of their regular migraine care. To investigate this, we conducted an online structured survey study among adult women who have been regularly using REN.


Study Design and Participants

This was a retrospective, observational survey study in which users of the REN device (Nerivio®, Theranica Bio-Electronics Ltd., Netanya, Israel) were contacted by an in-app notification and/or e-mail (provided by the users, during the sign-up process to the Nerivio app) and offered to participate. The study protocol (ClinicalTrial.Gov registration number NCT04600388) was reviewed and approved by the Western Institutional Review Board (WIRB) and was conducted according to Good Clinical Practice (GCP) and the Declaration of Helsinki guidelines.

The survey was sent to 455 female patients aged 18–55 across the United States who used Nerivio between October 1, 2019, and October 18, 2020, and completed at least four REN treatment sessions. The study sample represents a randomly selected sub-sample of Nerivio users who met the admission criteria. The sample size was calculated to achieve an approximate number of 100 completed surveys. Data were then excluded from the analysis if a patient’s report indicated that she was not menstruating, did not have menstrual migraines, or did not use the device to treat menstrual migraines (see Fig. 2 disposition chart). Menstrual migraine was defined according to the International Classification of Headache Disorders, third edition (ICHD-3; [2]), and reported as a yes/no question by the participants (Question text: “Do you usually experience migraines that occur 2 days before you get your period or during the first 3 days of your period (menstrual migraines)?”). Additionally, all participants were prescribed a migraine therapy by a neurologist.

Fig. 2
figure 2

Disposition chart

Before taking the survey, patients provided informed consent. The consent form appeared as the first page of the survey, and participants clicked either "agree" or "disagree" to the consent statement (those who clicked “agree” proceeded to the survey, and those who clicked “disagree” were brought to an exit page). Patients received a $10 gift card for participating in this survey. The first patient completed the survey on September 14, 2020, and the last patient completed the survey on October 20, 2020.

The REN Device

The REN device (Nerivio, Theranica Bio-Electronics Ltd., Netanya, Israel) and its mechanism of action have been described in detail elsewhere [17, 18]. Briefly, this is a wearable device worn on the upper arm upon the onset of migraine symptoms, the device is controlled by a smartphone application (the Nerivio app). It stimulates mainly C and Aδ noxious fibers for 45 min to activate an endogenous analgesic mechanism termed conditioned pain modulation (CPM) [13,14,15,16]. The stimulus pulse frequency is set at 100–120 Hz (modulated), with a pulse width of 400 μs, and the output current is up to 40 mA that can be adjusted by the patient. The stimulus is a modulated, symmetrical, biphasic square pulse.

Data Collection and Outcome Measures

Participants were asked to complete a 5-min online survey assessing satisfaction, effectiveness, and safety—using multiple-choice questions, open-ended questions, and rating questions. The primary endpoints were: effectiveness of REN for menstrual migraine and user satisfaction. Secondary endpoints included reported tolerability of the treatment, side-effect prevalence, effectiveness for menstrual cramps, and effectiveness for pelvic pain.

Data Analysis

Continuous variables were analyzed using mean and standard deviation. Ordinal and nominal variables are presented as the total number and percentage of patients in each category, per question. The multiple-choice questions concerning effectiveness and tolerability (Q3, Q6, Q8, Q9) were rated from least to most, and for those questions we present results ranging from moderate to extreme together (i.e., answers 3–5), along with separate rates of each of the answers. Question 2 (satisfaction) was rated on a five-point Likert scale (i.e., the middle answer was neutral), and thus results are presented separately for negative answers (1, 2), neutral answer (3), and positive answers (4, 5), along with rates of each of the five answers.

Data were analyzed using Microsoft Office Excel version 16 (Microsoft Inc., USA), and IBM SPSS statistics software version 23.0. (SPSS Inc., USA).



Out of 455 women who received the survey, 153 agreed to participate in the study. From those, the following were excluded (see Fig. 1 disposition chart): 36 participants who were not menstruating, 14 participants who did not have menstrual migraine, and 12 participants who did not use the device to treat menstrual migraines. This resulted in the inclusion of 91 participants in the analysis set. Participants were predominantly white (92.3% [84/91]), had a mean age of 35.2 ± 8.1, had an average number of 13.3 ± 8.7 headache days per month, and treated 4.9 ± 4.8 menstrual migraines with Nerivio (all participants used Nerivio at least four times to treat migraines, regardless of menstruation). Based on patient reports (in accordance with ICHD-3 criteria [2]), 88 (96.7%) women had menstrually related migraine (attacks occur especially but not only during the perimenstrual period [2]), and three women (3.3%) had pure menstrual migraine (attacks occur only with menstruation [2]). This ratio is consistent with the relative ratio of women with pure menstrual migraine in previous epidemiological studies estimating the population of women with migraine, which is 4% [26].

Menstrual Migraine Effectiveness


Of the participants, 74.7% (68/91) reported that the treatment was at least moderately effective (moderately effective 37.4%, very effective 26.4%, extremely effective 11.0%). The treatment was reported not effective in 25.3% (23/91) of the participant (slightly effective: 20.9%, not effective 4.4%).


Of the participants, 45.1% (41/91) reported satisfaction from REN (slightly satisfied 33%, extremely satisfied 12.1%), while 34.1% (31/91) were neutral, and 20.9% (19/91) were not satisfied (slightly dissatisfied 16.5%, not at all satisfied 4.4%).

Cramps and Pelvic Pain

Menstrual Cramps

Of the participants, 82.4% (75/91) indicated that they experience menstrual cramps. Out of these 75, 38.7% (29/75) reported that REN was at least moderately effective (moderately effective 28.0%, very effective 8%, extremely effective 2.7%) in treating the cramps. The treatment was reported not effective for cramps in 61.3% (46/75) of the participant (slightly effective: 29.3%, not effective 32.2%).

Pelvic Pain

Of the 91 participants, 38 patients (41.8%) indicated that they experience pelvic pain during menstruation. Out of these 38, 36.8% (14/38) reported that REN was at least moderately effective for the pelvic pain (moderately effective 28.9%, very effective 2.6%, extremely effective 5.3%). The treatment was reported not effective for pelvic pain by 63.2% (24/38) of the participant (slightly effective: 28.9%, not effective 34.2%).

Safety and Tolerability


Of the participants, 100% (91/91) reported that the treatment was at least moderately tolerable (moderately tolerable 8.8%, very tolerable 20.9%, extremely tolerable 70.3%).

Side Effects

Twelve patients (13.2%) reported mild short-term side effects: sore arm for several days after treatment (n = 1), bruise on the arm (n = 1), nausea (n = 2), dizziness (n = 1), drowsiness (n = 1), muscle twitching (n = 3), numbness in the arm during treatment (n = 2), and tingling in the arm and hand (n = 1).

Use of Rescue Medications

Sixty-nine of the participants reported their medication intake following REN treatments during the during the studied period. Of which, 40.9% (n = 27) had never taken any medications within 2 h from the treatment onset in any of the REN treatments they have done. 66.7% (n = 46) were medication free in at least 75% of the treatments, and 92.8% (n = 64) were medication free in at least 50% of their REN treatments.


The current survey study suggests that REN may offer an effective, well-tolerated treatment option for menstrual migraine. The study assessed real-world experience with REN for acute treatment of menstrual migraines by capturing reported effectiveness, satisfaction, and tolerability rates of the intervention via an on-line structured survey.

Our results show that nearly 75% of the participants reported that the treatment was at least moderately effective (with 37.4% of participants reporting it either very effective, or extremely effective), suggesting that REN may provide a non-pharmacological treatment option for women with menstrual migraine. The current results join a line of clinical studies with similar results. In a double-blind sham-controlled study in adults with episodic migraine [17], 66.7% of the participants achieved pain relief at 2 h post treatment (vs. 38.8% of participants in the sham group, with a therapeutic gain of 27.9%; p < 0.0001). Pain freedom and relief of most bothersome symptom were also significantly higher in the REN group compared to sham. A prospective, open-label dual-center study in adults with chronic migraine [23] indicated that 73.7% % of the participants achieved pain relief at 2 h post treatment. An open-label, single-arm, multicenter study in adolescents with migraine [24] also demonstrated pain relief in 71% of participants at 2 h, and improved functional ability in 69% of the participants. It should be noted that in the current study, data was collected differently (i.e., via patients’ retrospective global reports rather than after each treatment in a prospective clinical trial). However, while a randomized controlled trial is needed to further establish the therapeutic benefits, together these findings suggest that REN is an effective migraine treatment and could potentially offer much-needed relief in menstrual migraine as well.

Forty-five percent of the participants reported being either slightly satisfied or extremely satisfied (33.0%, 12.1%; respectively) more than twice the ratio of unsatisfied participants which was 20.9% (slightly dissatisfied 16.5%, not at all satisfied 4.4%). We acknowledge that while satisfaction rates were substantial, they are lower than effectiveness rates. This could reflect the fact that satisfaction is a complex construct, potentially combining factors like expectations for clinical efficacy, coverage by insurance, cost considerations, etc. We have chosen to assess both effectiveness and satisfaction, since they are both recommended endpoints according to the International Headache Society [27]. The finding that a considerable portion of the participants consider the treatment effective and satisfactory provides important information, as menstrual migraine attacks are typically more debilitating and less responsive to current acute treatments [4, 28].

All participants (100%) reported that the intervention was at least moderately tolerable (with 70.3% reporting it extremely tolerable, and 20.9% reporting it very tolerable). Twelve participants (13.2%) reported mild short-term side effects, most of which were expected and have been observed in previous studies [17, 23]. These results provide further support for the favorable tolerability and safety profile of REN found in clinical trials in episodic and chronic migraine in adults [16,17,18,19,20,21, 23], and adolescents [24].

Lastly, the study also examined whether REN treatment was reported to have an effect on two additional pain syndromes that afflict women during menstruation: menstrual cramps [29] and pelvic pain [30]. Nearly 40% of participants reported at least moderate effectivity for both symptoms (cramps 38.7%, pelvic pain 36.8%). while REN was not as highly effective for those symptoms as reported for migraine, the results suggest that it may offer a moderate degree of relief from cramps and pelvic pain for some patients. It should be noted that patients were not instructed to treat these syndromes, and effectivity might possibly improve if treated at onset (similarly to treatment instructions for migraine).

It should be noted that the effectivity and tolerability questions ranged from null to max (i.e., from ‘not effective’ to ‘extremely effective’), and thus the middle point of these scales was ‘moderately effective’ rather than ‘neutral’ that is often used in Likert scales. While a differently phrased scale could have resulted in a different breakdown of the results, we believe that this scale best suits the effectivity range, and we present it along with full specification of each category in the scale (e.g., moderately effective 37.4%, very effective 26.4%, extremely effective 11.0%…) for each question. Several limitations of this study should be noted. First, the retrospective self-report nature of the study may limit the conclusions of this survey by recall bias. While this is true, this study provides a naturalistic perspective on the effects of the treatment, and reflects the real-life perceptions that patients have on the intervention, in their own natural environment. The study is thus not intended to replace a randomized clinical trial (and is not presented as one), but rather to present the participants’ reports on their regular migraine care. Second, the diagnosis of menstrual migraine relied on self-report rather than a physician diagnosis. However, the report questions were identical to the ICHD-3 diagnosis criteria [2], and were answered as a yes/no response similar to the way a physician would diagnose. Lastly, only individuals who completed at least four REN treatments were sent a survey (possibly creating a selection bias). The sample thus represents REN users and is not meant to reflect the general population.


Menstrual migraine is more severe and harder to treat than non-menstrual migraine. The current survey study indicates that REN may provide a safe, non-pharmacological treatment option for women with menstrual migraine. While randomized controlled trials are needed to further establish the therapeutic benefits of REN in menstrual migraine, this study indicates that patients find REN effective and very well tolerated. It thus provides for the first-time evidence supporting this non-pharmacological treatment for menstrual migraine, for a population that long-awaits medical solutions.